Peptide therapy TikTok claims: what the science actually supports

What's this video probably claiming?

Accounts like @nursey_mercy operating in the peptide therapy space on TikTok typically make a familiar set of arguments: that peptides like BPC-157, TB-500, CJC-1295, ipamorelin, and GHK-Cu represent an underutilized class of compounds that can accelerate healing, improve body composition, and optimize growth hormone output. The nursing credential in the username adds a layer of perceived clinical authority. Given the category tag covering the full peptide roster, this video likely covers at least one of the big claims: faster tissue repair, fat loss with muscle preservation, or anti-aging skin effects. Some creators in this space also push MK-677 as a growth hormone secretagogue that "works like" prescription GH therapy. Whether this video crosses into disease-cure territory or dosing recommendations is unknown until transcript review, but the pattern is common enough to flag in advance.

What does the science actually show?

The honest answer is: it depends sharply on the specific peptide. BPC-157 has genuine preclinical data. A 2018 study by Sikiric et al. in Current Pharmaceutical Design documented consistent healing effects in rat models of tendon, gut, and bone injury. The problem is that "preclinical" means rats, not humans, and no randomized controlled trial in humans has been published as of 2024. TB-500, a thymosin beta-4 fragment, has similarly promising animal data but zero published human RCTs. CJC-1295 with DAC does demonstrably raise IGF-1 levels: a 2006 study by Jetté et al. in the Journal of Clinical Endocrinology and Metabolism showed sustained IGF-1 increases of 28-43% with twice-weekly dosing in healthy adults, but the clinical implications for non-deficient individuals remain unclear. GHK-Cu has legitimate wound-healing and collagen synthesis data in cell cultures and small human topical trials, but injectable GHK-Cu claims outpace the evidence significantly.

Where does the social media noise diverge from clinical reality?

The gap is widest in three areas. First, animal-to-human translation. Rat studies on BPC-157 use intraperitoneal injection at doses that don't map cleanly onto subcutaneous human dosing, yet creators often cite these studies as if the results transfer automatically. Second, the regulatory context. Most injectable peptides discussed in this space are compounded, not FDA-approved, which means quality control varies by pharmacy and no standardized manufacturing process applies. Third, MK-677 is frequently described as a peptide when it is actually a non-peptide ghrelin mimetic and orally active growth hormone secretagogue. A 2008 study by Nass et al. in the Annals of Internal Medicine found MK-677 at 25 mg daily increased IGF-1 but also increased fasting glucose and insulin resistance, a side effect profile that rarely makes it into TikTok content. Semax and selank, the nootropic peptides, have a Russian clinical literature base that is difficult to independently verify by Western evidence standards.

What should you actually know?

If you are considering any peptide therapy, the starting point matters more than the compound. A licensed provider should evaluate your baseline IGF-1, glucose metabolism, and health history before any growth hormone axis peptide is considered. The FDA has not approved BPC-157, TB-500, or most other peptides in this category for any therapeutic indication in humans. The compounding pharmacy route is legal in specific contexts under provider supervision but carries real variability in purity and concentration. Peptides sourced from research chemical vendors are explicitly not for human use, regardless of what TikTok suggests. Cost also matters: CJC-1295 and ipamorelin stacks from legitimate compounding pharmacies typically run $150-400 per month depending on dose and formulation, and that cost is almost never covered by insurance. Expect the evidence base to improve over the next five years as clinical trials catch up to the hype, but right now, most of this space runs well ahead of what peer-reviewed human data can support.